Unless a court or Congress intervenes, the 340B Rebate Model Pilot takes effect January 1, 2027. HRSA has approved 10 drug manufacturers and 21 drugs for the pilot, which replaces the upfront 340B discount with a back-end rebate for those products.
Where Things Stand
- In court: The American Hospital Association and partners sued again to block the pilot. Drugmakers have asked to intervene, and the AAMC joined an amicus brief opposing implementation.
- In Congress: A bipartisan House bill, H.R. 10770, would delay the pilot by two years, to 2029, and preserve upfront discounts in the meantime. Senate discussion also continues around the SUSTAIN 340B Act.
- On cost: Hospitals estimate the pilot would cost them more than $1 billion a year in administrative burden and carrying costs. Yahoo Finance notes some may need to borrow to bridge the gap.
- On data: Separately, Missouri’s attorney general ordered Eli Lilly to end a requirement that 340B hospitals submit claims data for every dispensation, a reminder that manufacturer conditions are still being contested.
Why Rebate Timing Matters
Under a rebate model, a covered entity pays a higher price at purchase and then submits data to receive the 340B difference later. The total savings may be similar on paper, but the cash-flow gap between purchase and rebate is real. Even with HRSA’s 10-calendar-day payment-or-denial requirement following a complete submission; purchasing, dispensing, submission and reconciliation can create working-capital needs. Clinics should model their own timelines rather than assume a fixed rebate delay.
How to Check Your Clinic’s Readiness
- Map your exposure. Compare your dispensing data against the 21 pilot drugs and estimate the monthly dollar amount that will shift from discount to rebate.
- Set a reserve target. Hold enough unrestricted 340B savings to cover at least one to two months of premium obligations.
- Tighten your data. Rebate claims will depend on clean, timely submissions. Confirm your vendor partners are ready, and the right partners for the job.
- Brief leadership and your board. Make sure decision-makers understand the timing risk and the contingency plan before January.
Planning for PIAP Funding During the Transition
A premium insurance assistance program is one of the most efficient uses of 340B savings because it converts discounts into commercial coverage, which in turn generates insurance reimbursement and further 340B-eligible dispensing. Protecting that cycle during the rebate transition is about planning. The financial impact will vary by drug mix, dispensing volume, available reserves and rebate-processing performance.
American Exchange helps covered entities model 340B revenue under the rebate pilot, size PIAP reserves and adjust premium payment schedules so clients have a lower risk of coverage interruptions. Whether the pilot launches on schedule or is delayed, the planning you do now will make your program more resilient.
Sources
- Modern Healthcare – HRSA 340B rebate pilot to include 21 drugs, 10 drugmakers
- AHA – AHA urges court to reject drug industry intervention in 340B rebate program case
- AAMC – AAMC-Endorsed Legislation to Delay 340B Rebate Model Pilot Introduced in Congress
- Medical Daily – 340B Rebate Pilot Would Cost Hospitals Over $1 Billion a Year, They Say
- Yahoo Finance – Changes to This $100 Billion Federal Drug Program Could Make Banks the Hidden Beneficiaries
- HealthLeaders Media – 340B Rebate Fight Puts Hospital Cash Flow on the Line
- Becker’s Hospital Review – Missouri attorney general orders Eli Lilly to end 340B claims data requirement
- AHA – AHA comments on the SUSTAIN 340B Act
